Physician profile
Alan L Ho
NPI 1851567879
$28,274.35
in general payments reported to CMS, 2019-2025
15 companies · $14K in 2025
The $14K reported for 2025 was more than what 84% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.16 · 2020: $1,250 · 2021: $6,225 · 2022: $3,154 · 2023: $3,910 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $1,396 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,320 · Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,567.50 |
| Travel and Lodging | $1,396.07 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,320.00 |
| Food and Beverage | $287.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $7,635.00 | 2020-2023 | |
| Glaxosmithkline, LLC. | $6,548.48 | 2025 | |
| Exelixis INC. | $4,739.70 | 2021-2023 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $3,100.00 | 2025 | |
| Day One Biopharmaceuticals | $2,250.00 | 2025 | |
| Merck Sharp & Dohme LLC | $2,135.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $1,762.50 | 2025 | Rybrevant |
| Lilly USA, LLC | $75.16 | 2019 | |
| Abbvie INC. | $28.51 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.